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SUMMARY
Introduction: Tuberculosis (TB) is the commonest cause of morbidity and mortality
among people living with human immunodeficiency virus (PLHIV). At least one in
four deaths among people living with HIV can be attributed to TB, and many of these
deaths occur in developing countries. Ethiopia is one of the highly affected countries
by the TB/HIV co-infection epidemic. But there is no study conducted regarding the
probabilities of developing TB and the potential predictors among HIV patients in the
study area.
Objective: the aim of this study is to assess incidence of Tuberculosis and
Predictors among people living with HIV attending adult HIV care clinic at University
of Gondar Referral Hospital.
Methods: Institution based retrospective follow up study will be conducted at
University of Gondar Referral Hospital Adult HIV care clinic. All 1838, patients above
the age of 15 who were newly enrolled in HIV care clinic from October, 2006 to
December, 2007 will be included. The study subjects will be followed retrospectively
for five years (until December 31, 2011). The data will be entered to EPI- INFO
version 3.6.1 then export to STATA 11for analysis. Kaplar-meier will be used for
analysis of probabilities of developing TB. Log rank tests will be used to compare
survival curves between the different categories of the explanatory variables. Both
bivariate and multivariate Cox proportional hazards model will be fitted to identify the
predictors. The necessary assumption of Cox proportional hazard model will be
checked by using schoenfield residuals test.
Budget and work plan- The research will be conducted from February to April,
2012 and a total of 15,788.30 Birr is required to carry out this study.
11. INTRODUCTION
1.1. Statement of the problem
Tuberculosis (TB) is the most frequently diagnosed opportunistic infection and
disease in human immunodeficiency virus (HIV) infected patients world-wide (1, 2).
Despite being preventable and curable, it is still a leading killer of people living with
HIV. At least one in four deaths among people living with HIV can be attributed to
TB, and many of these deaths occur in developing countries (3). Worldwide about
11.1 million adults are co-infected with TB and HIV. Seventy percent of co-infected
people are living in sub-Saharan Africa (4). An especial  important aspect of the
public health impact of HIV/AIDS has been the secondary epidemic of TB, most
severe in area where rates of HIV infection are highest (5).
Globally, just over one in ten of the almost 9 million people who develop TB each
year are HIV-positive; Of the 8.8 million incident cases in 2010, 1.1 million [1.0
million– 1.2 million]  were among people living with HIV.  The proportion of TB cases
co infected with HIV is highest in countries in the African Region; overall, accounted
for 82% of TB cases among people living with HIV. Globally in 2010, there were an
estimated 0.35 million deaths from TB among people who were HIV-positive(6).
In the year 2009, TB is estimated that globally there were 9.4 million incident TB
cases and there were 1.3 million TB deaths. The incidence rate, prevalence rate and
mortality rate due to TB is highest in Africa. TB-HIV co-infection and drug resistant
tuberculosis aggravate the TB situation globally. Of the 9.4 million incident cases in
2009, an estimated 1.1 million (12%) were HIV-positive. Of these HIV positive cases,
78% were in  African (7).
The principal reason for the resurgence of TB in Africa is not the deterioration of
control programs. Rather, it is the link between TB and HIV/AIDS. People who are
latently infected with Mycobacterium tuberculosis—about one-third of the inhabitants
of Sub-Saharan Africa are at hugely greater risk of developing active TB if they are
also immunologically weakened by a concurrent HIV infection (8).
2TB is one of the conditions associated with HIV infection for which cure is possible
with appropriate therapy but untreated TB can accelerate the course of HIV
infection. In an individual infected with HIV, the presence of TB may affect in many
ways. TB increase HIV replication, which leads to increased viral load. These result
in more rapid progression of HIV diseases.  TB increases the occurrence of other
opportunistic infections. It is also harder to diagnose in someone infected with HIV
because the clinical manifestations of TB in HIV-infected patients are quite varied
and generally show differently. One third of all people living with HIV worldwide are
latently infected with Mycobacterium tuberculosis (MTB), making them 21-34 times
more likely to develop active TB disease than people who are HIV negative (9-11).
The management of TB and HIV co-infected individual is challenging because of: pill
burden(12) increase adverse effect(13), drug to drug interaction (14) and immune
reconstitution inflammatory syndrome (IRIS) (15) due to this TB become the number
one cause of mortality among people living with HIV (PLHIV). Late TB diagnosis
contributes to increased death rates in PLHIV (4).
In Ethiopia, TB/HIV co-infected patients had greater risk of common mental
disorders, lower quality of life, low family income and  poor physical health than HIV
infected patients without active TB (16, 17). Ethiopia ranks seventh among the
world’s 22 high-burden tuberculosis countries. It is also one of the highly affected
countries by the TB/HIV co-infection epidemic. According to the World Health
Organization’s (WHO’s) Global TB Report 2009, the country had an estimated
314,267 TB cases in 2007, with an estimated incidence rate of 378 cases per
100,000 population.  The number of TB cases is likely to increase as Ethiopia’s
HIV/AIDS epidemic expands; while 16 percent of notified TB patients tested for HIV,
40 percent are HIV positive. Hence, the concomitant epidemics of HIV and
tuberculosis are a major public health problem in Ethiopia; a TB/HIV collaborative
program was launched since 2002 prior to WHO recommendation (2004)(18, 19).
31.2. Literature review
Different studies have documented the increased risk for TB among HIV-infected
adults. According to a Taiwan short Report in 2009, the incidence rate of TB/ HIV co-
infection among HIV cases varies during pre-free HAART era and post-free HAART
era.  It rose from 1.90% to 3.82% during 1993 to 1998 and decreased from 3.82% to
0.94% during 1998 to 2006. This study showed that Highly active antiretroviral
therapy decreased the incidence rate of new TB/HIV co-infection cases among HIV
cases and increased the survival rate of TB/HIV co-infection cases from 62.16%
during the pre-free HAART era  to 86.60% during  post-free HAART era(20).
A cohorts study in the United States and Canada on 37 845 persons infected with
HIV who initiated HAART revealed that 0.4% were diagnosed with tuberculosis after
HAART. From This study, black race and baseline CD4 T lymphocyte count <200
cells/mm3 Were among the independent risk factors associated with tuberculosis
diagnosis after HAART initiation(21). Another study showed that the majority of TB/
HIV co-infection were common in young adults (median age 34.7 years, IQR  30.1–
40.3) and black Africans(22).
The use of both IPT and ART in HIV-infected patients significantly reduced
tuberculosis incidence. retrospective medical record review  in 11 026 HIV-infected
patients receiving medical care at 29 public clinics in Rio de Janeiro, Brazil, showed
that The overall tuberculosis incidence was 2.28 cases/100 person-years.  Among
patients who received neither ART nor IPT, incidence was 4.01/100 PY. Patients
who received ART had an incidence of 1.90/100 PY and those treated with IPT had
a rate of 1.27/100 PY. The incidence among patients who received ART and IPT
was 0.80/100 PY.  Multivariate Cox proportional hazards modeling revealed a 76%
reduction in tuberculosis risk among patients receiving both ART and IPT (23).
In a ten years prospective study done in West Africa among 368 HIV- 1 infected
adults the incidence rate of tuberculosis was 3.8/100 person-year. And it was
diagnosed a median of 5.4 [interquartile range (IQR), 1.9–23.1] months after HIV
diagnosis. The majority of those with incident TB (86.8%) had pulmonary TB.
4The Incidence was highest in the group with low CD4 cell count, <200 106 cells/l.
and with older age(24).
Results from placebo-controlled trial of 93 subjects in Dar es Salaam, Tanzania,
among HIV-Infected Ambulatory Subjects found that Clinical and subclinical
tuberculosis are common among ambulatory HIV-infected persons, and   active
tuberculosis was 15%  of them 71%  had clinical tuberculosis (symptoms or chest
radiograph findings), and  29% had subclinical tuberculosis (positive sputum AFB
stain or culture results but no symptoms or chest radiograph findings)(25). Another
randomized control trial done in south Africa on adults living with HIV suggest that
more widespread use of isoniazid preventive therapy is essential to control the
epidemic of HIV related tuberculosis (26).
A cross sectional study conducted at Haydom Lutheran Hospital in northern rural
Tanzania among 233 HIV/AIDS patients with age of 10 years and above revealed a
high prevalence of tuberculosis (8.5%). Tuberculosis can occur at any stage of
CD4+T cells depletion(27)
Another, Cross sectional record review on 1320 HIV/AIDS patients in Aminu Kano
Teaching Hospital, Northern Nigeria 10.5% were co infected with TB (95% CI, 8.9%
to 12.2%). Pulmonary TB was diagnosed in 74.6% patients, among whom only
17.5% were sputum-positive.  The highest prevalence of TB, 13.7% (n = 28), was
seen among patients aged 41–50 years. TB co infection was significantly associated
with marital status, WHO clinical stage and CD4 count (28).
Results from a multi-centered cohort study in 8 Sub-Saharan African countries on
30,134 adult showed that the incidence of tuberculosis was 10.5 per 100 person
years during the pre-ART and 5.4 during the ART period. For all types of
tuberculosis, incidence was similar in the pre-ART period and initial 3 months of ART
but declined over time receiving ART (from 13 per 100 person-years in the first 3
months to 1.5 per 100 person-years after 12 months of therapy). It also showed that
throughout the follow-up period, rates of pulmonary tuberculosis remained 2-fold to
3-fold higher than extra pulmonary tuberculosis rates. Incidence was lower in rural
sites, women, patients without prior history of tuberculosis, body mass index > 18.5
5kg/m2, and > 200 nadir CD4 cells per microliter. The recurrence rate was 1.7 per
100 person-years (29).
The risk of developing tuberculosis among persons infected with HIV  has been
reported to be extremely high in the first 3 months after initiation of highly active
antiretroviral therapy (HAART), with rates ranging from 1300 to 1700 per 100 000
person-years in developed countries  and from 10 700 to 23 000 per 100 000 person
years in developing countries (30, 31)
Evidence from, Prospective observational study in Mulago Hospital, Uganda;
showed that Female sex (adjusted hazard ratio [aHR], 1.4) and baseline BMI ≤ 20
(aHR 1.9) predicted incident of TB in TB-HIV co-infections among patients with and
without ART(32).
Ethiopia is one of the high burden tuberculosis countries.  A retrospective review
from five high burden tuberculosis countries revealed that in a very high TB burden
countries  incidence rates of  TB among individuals on HAART is  higher( Malawi ,
14.3/100 person-years and Kenya, 17.6/100 person-years ) as compared to low TB
burden countries (33).
In a cohort of 185 pre-HAART and 180 HAART HIV patients done in Ethiopia the
incidence rate of tuberculosis was 11.1 per 100 PYO (9 cases per 80.9 PYO) and
3.7 per 100 PYO (6 cases per 162.2 PYO) respectively. The median time to the
diagnosis of tuberculosis in HAART cohort was 32 weeks (IQR, 14–56). The result
showed that Tuberculosis incidence rate was lower in the HAART group. History of
easy fatigability  and prolonged fever predicted tuberculosis in the pre-HAART group
but not in the HAART group (34). In another retrospective study done among 300
PLHIV attending an HIV care clinic in Dil Chora Referral Hospital, Ethiopia, during a
12-month period showed that 11% patients were diagnosed with TB, of whom 79%
were identified in the first 6 months. And 15%of TB cases were smear-positive PTB
while 53% were smear-negative PTB with 17% extra pulmonary TB (EPTB) (35).
6Fig. 1 Conceptual frame work which shows the occurrence of tuberculosis
among HIV patients.
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71.3. Justification of the study
Tuberculosis is the commonest cause of morbidity and mortality among PLHIV. It is
also special in HIV infected patient because it increases the occurrence of other
opportunistic infections and it occurs at various WHO clinical stage of HIV infection.
In addition to this; unless we prevent in advance by identifying the potential risk
factors, the anti TB treatment takes a long time unlike other OI’s treatment which
create pill burden for those who are on HAART.
In recent years, great efforts have been made to integrate tuberculosis diagnosis
and treatment into HIV care which are essential to prevent, diagnose and treat TB
among people with HIV and HIV among TB patients. This has created the need for
additional research for better understanding of factors associated with incident
tuberculosis which could help to improve service provision.
In University of Gondar Referral Hospital there are about 6444 and 3888 who ever
stared and currently on ART respectively. However; the TB incidence rate and
associated factors for TB are not studied yet. Therefore, this study will be important
to show the incidence rate of TB in adult living with HIV and the possible predictors
of the disease that can be addressed to reduce the occurrence of Tuberculosis
among HIV patients.
82. OJECTIVE
2.1. General objective
 To assess incidence and Predictors of Tuberculosis among adults living with
HIV attending HIV care clinic at University of Gondar Referral Hospital.
2.2. Specific objectives
 To determine incidence rate of Tuberculosis among adults living with HIV
attending HIV care clinic at University of Gondar Referral Hospital.
 To identify the predictors of Tuberculosis among adults living with HIV
attending HIV care clinic at University of Gondar Referral Hospital.
93. METHODS
3.1. Study design
A five years institution based retrospective follow up study will be conducted.
3.2. Study area and period
The study will be conducted at University of Gondar Referral Hospital HIV care clinic
from February to April, 2012. It is located in North Gondar administrative zone,
Amhara National Regional state, which is far from about 727 km Northwest of Addis
Ababa (the capital city of Ethiopia). According to the 2007 population and housing
census report , the total population size of Gondar town was estimated to be
206,987 (36). This Town is  experiencing fast growth and according to the Gondar
Town Health office report  currently it has 209,163 populations(37). Currently
Gondar town has one referral hospital and five government health centers.
University of Gondar Referral Hospital is a teaching Hospital which serves more than
five million people of the North Gondar zone and peoples of the neighboring zones.
The HIV care services of the Hospitals were initiated in 2005 and have three clinics:
Adult ART clinic, Pediatric ART clinic, and VCT clinic. The clinic has two medical
doctors providing ART services, 1 MPH in reproductive Health, 2 Health officers , 2
BSc and 4 Diploma  nurses,   2 data clerks, 2 data base manager,1 porter, 2 janitors
3 case manager and 8 adherence supporters (people living with HIV). The hospital
uses standardized monitoring and evaluation tools and the data collection and
management process is well controlled and supported by electronic data back-up
and processing. There were about 6444 and 3888 who ever stared and currently on
ART respectively. There were about 1,838 adults newly enrolled in to chronic HIV
care and support program in the year 2006/2007.
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3.3. Source and Study Population
The source population is all Adults living with HIV in University of Gondar Referral
Hospital HIV care clinic. The study population will be those Adults living with HIV
who were newly enrolled in HIV care clinic from October, 2006 to December, 2007.
Inclusion and Exclusion Criteria
Inclusions:
 All PLHIV aged 15 years and above who were newly enrolled in to HIV care
clinic from October, 2006 to December, 2007 and
 PLHIV on HIV care clinic follow up program who had at least six months of
follow up in the hospital.
Exclusions:
 PLHIV on HIV care clinic who had incomplete base line information (like age,
sex, residence, CD4 counts, haemoglobin level) in the records.
3.4. Sample size and sampling procedures
All people living with HIV who were registered from October, 2006 to December,
2007 in Adult HIV care clinic of the University of Gondar referral hospital will be
included in the study and followed them for five years (until December 31, 2011).
All 1,838 adults who were newly enrolled to HIV care and support during 2006/2007
will be included in the study provided that they fulfill the inclusion criteria. This period
is selected in order to have a nearest five year follow up study periods and more or
less the facility started full implementation of standardized formats, documentation
and recording system in regular manner since this period. This is critical as the study
is based on secondary data and it is also important to make sure that important
variable for the study should be available for all enrolled subjects in the study. The
likelihood of obtaining complete information on the variables for the study is very
high during this period.
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3.5. Variables of the Study
3.5.1. Dependent variable of the study will be the time of occurrence of
tuberculosis in adults living with HIV who are on care and support in the
Hospital.
3.5.2. Independent variables of the study:
Socio-demographic characteristics: Age, Sex, Residence, Family size,
Educational level and Occupation, substance abuse.
Baseline clinical characteristics: WHO clinical Stag, CD4 counts/ total lymphocyte
count (TLC), Haemoglobin level (Hgb), Body mass index (BMI)
Follow-up clinical and treatment related characteristics: INH prophylaxis
therapy (IPT), co-trimoxazole Prophylactic therapy (CPT), ART drug regimen,
Adherence, Co-morbid conditions (other OIs), Prior history of tuberculosis,
Functional status, Presence of drug side effect
3.6. Operational definitions
Events - New or incident TB, which is defined in this study as the occurrence of TB
in people living with HIV any time after enrolled it to HIV care. The type of TB can be
smear positive pulmonary, smear negative pulmonary, extra-pulmonary or
disseminated tuberculosis as identified by signs and symptoms, laboratory and/or X-
ray diagnosis.
Censored – the survival time is censored when the individual is lost, drop out,
transfer out and died by other causes before the end of the study period and finished
the period without developing the event.
Lost- patients missing their appointment for follow up or drug pick up at least for one
to three months.
Drop out- patients missing their appointment for follow up or drug pick up for more
than three months
Transferred out – those patients who are transferred to other health care facilities
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Body Mass Index (BMI): is the ratio of weight to height in meters squared; And it
will be classified as (38): <18.5 = Underweight, 18.5-24.9 = Normal weight, 25-29.9
= Overweight, 30 and above=Obese.
Adherence to ART: will be classified in to good, fair, and poor according to the
percentage of drug dosage calculated from the total monthly dose of ART drugs.
Which describe as Good (equal to or greater than 95% or ≤ 3 doses missed per
month), Fair (85- 94% or 4-8 doses missed per month), or Poor (less than 85% or ≥
9 doses missed per month)(39).
3.7. Data Collection Tools and Procedures
The available information on the patient records has been first observed and
appropriate data extraction tool has been prepared in English. Using this format,
staffs who are working on the HIV care clinic will collect the data on the already
existing records.
3.8. Data quality control
Quality of data will be maintained by recruit staffs for the data collection who are
working at the HIV care clinic. The data collectors and supervisor will be given
intensive training for one day before the data collection on the objective of the study
and how to retrieve data for this study purpose using the data extraction format.
They will be briefed on the definition of variables on the questionnaires and
registration charts. The data extraction tool will be pre-tested for consistency of
understanding and completeness of data items on 25 charts at the same facility as
it is a secondary data. The retrieval process will be closely monitored by the
principal investigator and the supervisor throughout the data collection period.
Completed questionnaires will be checked regularly for completeness of information
and any gaps identifies will be immediately communicated to the data collectors.
Double entry will be done on 10% of the questionnaires.
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3.9. Data processing and analysis
After the data checked for its consistency and completeness, it will be entered to
EPI- INFO version 3.6.1 then exported to STATA 11 for analysis. Data entry will be
conducted by the principal investigator and it will be cleaned before analysis.
Descriptive and summary statistics will be carried out. Incidence density (ID) will be
calculated for the entire study period. Kaplan-Meier plots will be used for analysis of
probabilities of developing TB. Generalized log rank tests will be used to compare
survival curves between the different categories of the explanatory variables.
Both bivariate and multi variate Cox proportional hazard model will be used to
identify the predictors. Variables having p value up to 0.2 (20%) in the bivariate
analysis will be fitted in to the multi variate model. Ninety five percent confidence
interval of hazard ratio will be computed and variable having p value less than 0.05
in the multi variate cox proportional hazards model will be considered as significantly
associated with the dependent variable. The necessary assumption of cox
proportional hazard model will be checked by using schoenfield residuals test.
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4. ETHICAL CONSIDERATION
Ethical clearance will be obtained from the Institution review board of University of
Gondar, Institute of Public Health. Permission will be obtained from the Hospital’s
management and HIV care clinics focal person to use the secondary data for the
purpose of this study. The name or any other identifying information will not be
recorded on the questionnaire and all information taken from the chart will be kept
strictly confidential and in a safe place. The information retrieved will only be used
for the study purpose.
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5. DISSEMINATION OF RESULTS
The final result of the study will be summated as partial fulfillment of the degree of
Master of Public Health in epidemiology and biostatistics to the institute of Public
Health, College of Medicine and Health Sciences, University of Gondar.
It will be disseminated to university of Gondar Referral Hospital, Amhara regional
Health bureau, North Gondar Health Department and other governmental and none
governmental organizations who are specially working on HIV/AIDS and
Tuberculosis. The result will be also presented at University of Gondar annual
research conference, Ethiopian Public Health Association Annual Conference and
other conferences and workshops. Moreover, the result will be sent for publication at
scientific National or international journals.
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6. WORK PLAN
NB: PI=Principal Investigator DC= Data Collector S=Supervisor R= Responsible body
RPO= Research Publication Office
Activities R January February March April May June
Topic selection PI
Topic defense PI
Proposal
preparation
PI
First draft
proposal
submission
PI
Proposal
defense
PI
Final proposal
submission
PI
Ethical
clearance
RPO
Training of
data clerk
PI
Pre test PI,DC
Data collection
& entry
DC,S
Data analysis
& write up
PI
First draft
submission
PI
Submission of
final thesis
PI
Preparation for
thesis defense
PI
Thesis defense PI
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7. COST OF THE RESEARCH PROJECT
Personnel costs
Title Qualification Number of
personnel
Per dime Duratio
n (days)
Total cost Remark
Supervisors Physician, BSc.
Nurse or HO
1 70.00 18 1260.00 Training, pretest &
data collection
data collectors BSs nurse 4 58.00 18 4176.00 ,,
data clerk Diploma nurse 1 58.00 18 1044.00 ,,
Data enter MPH students 1 70.00 15 1050.00 Principal investigator
Data analysis MPH students 1 70.00 15 1050.00 Principal investigator
secretary 1 58.00 10 580.00
Total 8104.00
Equipment and Supplies
Equipment &
Supplies
Units Quantity Unit cost Total cost
Paper Rim 10 120.00 1200.00
Stapler Number 1 50.00 50.00
Staples Pack 2 10.00 20.00
Eraser Number 5 1.00 5.00
Pen Number 18 2.50 45.00
Pencils Number 18 .50 9.00
Note book Number 10 10.00 100.00
Printing Page 110 2.00 220.00 For the
questionnaire,
proposal and thesis
Duplication Page 7000 0.50 3500.00 ,,
Binding Number 10 10.00 100.00 ,,
Flash disc Number 1 400.00 400.00
CD-RW Number 8 25.00 200.00
Mobile cared Number 3 100.00 300.00 For communication
packed  water Number 10 10.00 100.00 During training
Total 6249.00
Budget summary
1. Sub total cost for personnel 8104.00
2. Sub total cost for materials and supplies 6249.00
Total 14,353.00
10% contingency 1435.30
Grand total 15788.30
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9. ANNEX
Annex 1 - information sheet
Title of the Research Project: Incidence of Tuberculosis and Predictors among HIV
infected patients attending adult HIVcare clinic at University of Gondar Referral
Hospital, Northwest Ethiopia.
Name of Investigator: Kefylalew Addis (Bsc in Public Health Officer)
Name of the Organization: University of Gondar College of Medicine and Health
Sciences, Institute of Public Health.
Name of the Sponsor: University of Gondar
Introduction: this information sheet is prepared for University of Gondar Referral
Hospital administration and Hospital HIV care clinic coordinating office. The aim of
the form is to make the above concerned office clear about the purpose of research,
data collection procedures and get permission to conduct the research.
Purpose of the Research Project: To determine incidence of Tuberculosis and its
Predictors among adult living with HIV attending adult HIV care clinic at University of
Gondar Referral Hospital.
Procedure: In order to achieve the above objective, information which is necessary
for the study will be taken from HIV care medical record follow up forms.
Risk and /or Discomfort: Since the study will be conducted by taking appropriate
information from medical chart, it will not inflict any harm on the patients. The name
or any other identifying information will not be recorded on the questionnaire and all
information taken from the chart will be kept strictly confidential and in a safe place.
The information retrieved will only be used for the study purpose.
Benefits: the research have no direct benefit for one whose document/ record is
included in this research. But the indirect benefit of the research for the participant
and other clients in the program is clear. This is because if program planners are
preparing predicted plan there is a benefit for clients in the program of getting
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appropriate care and treatment services.  Of all, the research work has a paramount
direct benefit for health care planners and managers, especially for those on HIV/TB
collaborative program planning and management.
Confidentiality: to reassure confidentiality the data on the cart will be collected by
those individuals who are working on the HIV care clinic in the facility and
information will be collected without the name of the clients. The information
collected from this research project will be kept confidential and will be stored in a
file. In addition, it will not be revealed to anyone except the investigator and it will be
kept in key and locked system with computer pass ward.
Person to contact: This research project will be reviewed and approved by the
institutional review board of College of Medicine and Health Science, University of
Gondar. If you want to know more information, you can contact the committee
through the address below. If you have any question you can contact any of the
following individuals (Investigator and Advisors) and you may ask at any time you
want.
1. Kefyalew Addis, University of Gondar, College of Medicine and Health
Science, Department of Health Officer: principal investigator
Cell phone: +251- 09 20 25 66 99
E-mail: kefadis@gmail.com
2. Dr.  Belaynew Wassie, University of Gondar, College of Medicine and Health
Science, institute of Public Health: Advisor
Cell phone: +251-09 13 47 43 98
E-mail: bewasie@yahoo.com
3. Ansha Nega (RS, BSc, MSc) University of Gondar College of Medicine and
Health sciences ,Department of Environmental and Occupational Health and
safety: Advisor
Cell phone: +251-09 18 15 10 73
E-mail: ains262000@gmail.com
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የመረጃ እና ስምምነት ዉል ቅጽ
የምርምሩ/ጥናቱ ርዕስ ፡
በጎንደር ዩንቨርሲቲ ሪፈራል ሆስፒታል የኤች አይ ቪ ክትትል ባላቸዉ አቂዎች ላይ
ክትትል ከጀመሩ በኋላ ያለዉን የሳንባ ነቀርሳ ክስተት እና ተዛማጅ ምክንያቶችን
በተመለከተ
የዋና ተመራማሪ ስም ፡ ከፍያለዉ አዲስ
የድርጅቱ ስም ፡- በጎንደር ዩኒቨርሲቲ ህክምናና ጤና ሳይንስ ኮሌጅ የህብረተሰብ ጤና
አጠባበቅ ተቋም
ወጭውን የሚሸፍነው አካል፡- ጎንደር ዩኒቨርሲቲ
መግቢያ፡
ይህ የመረጃ እና የስምምነት ዉል ቅጽ የተዘጋጀዉ ለጎንደር ዩንቨርሲቲ ሪፈራል
ሆስፒታል አስተዳደር እንዲሁም በሆስፒታሉ ለሚገኘዉ የኤች አይ ቪ ክሊኒክ ክትትል
ሀላፊ ነዉ። ዋና አላማዉም ስለ ምርምሩ ዓላማ ፤ ስለ መረጃ አሰባሰቡ ፤ እንዲሁም
ጥናቱን ለማካሄድ ፍቃድ ለማግኘት ከላይ የተጠቀሱት አካላት ግልጽ እንዲሆንላቸዉ
ለማድረግ ነዉ።
ጥናቱ የሚካሄድበት ምክንያት፡
የዚህ ጥናት ዋና አላማ በጎንደር ዩንቨርሲቲ ሪፈራል ሆስፒታል የኤች አይ ቪ ክትትል
ባላቸዉ አቂዎች ላይ ክትትል ከጀመሩበት ጊዜ አንስቶ ያለዉን የሳንባ ነቀርሳ ክስተት
እና ተዛማጅ ምክንያቶችን ለማጥናት ታቅዶ የተዘጋጀ ነዉ ።
አተገባበር
የጥናቱን አላማ ለማሳካት በጎንደር ዩንቨርሲቲ ሪፈራል ሆስፒታል የኤች አይ ቪ
ክትትል ባላቸዉ የአዋቂዎች ቻርት ላይ መረጃዉ ይሰመሰባል።
ሊገጥም የሚችል ችግር /አለመመቸት
የሚወሰደዉ መረጃ ሙሉ በሙሉ ከቻርት ላይ ብቻ ስለሆነ በበሽተኞች ላይ ምንም
አይነት ጉዳት አያመጣም። የቻርቱ ባለቤት ስምና መለያ ቁጥር ከመጠይቁ ላይ
አይገለጽም። በተጨማሪም የተሰበሰበዉ መረጃ በደንብ ተቆልፎ ይቀመጣል እንዲሁም
ለታቀደለት አላማ ብቻ ይዉላል ።
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ጥቅሞች
በዚህ ጥናት ተሳታፊ የሚሆኑ ሰዎች በቀጥታ ሊያገኙት የሚችሉት ጥቅም የለም ።
ቢሆንም ግን መረጃቸዉ የኤች አይ ቪ ክትትል ባላቸዉ አቂዎች ላይ ክትትል
ከጀመሩበት ጊዜ አንስቶ ያለዉን የሳንባ ነቀርሳ ክስተት እና ተዛማጅ ምክንያቶችን
ለማጥናት ይጠቅማል። ከጥናቱ ዉጤት ተነስቶ በሚደረገዉ የፕሮግራም መሻሻል
በቀጥታም ባይሆን ተጠቃሚ ይሆናሉ።
ሚስጥራዊነት
ለዚህ ጥናት የሚሰበሰበዉን መረጃ ሚስጥር ለመጠበቅ ሲባል መረጃዉ የሚሰበሰበዉ
በሆስፒታሉ ዉስጥ በሚገኘዉ የኤች አይ ቪ ክሊኒክ በሚሰሩ ነርሶች ነዉ ። ከዚህ በኋላ
የተመረጡት ነርሶች በቻርቱ ላይ የሚገኘዉን መረጃ ይሰበስባሉ ። የተሰበሰበዉ
መረጃም ከጥናቱ ዋና ተመራማሪ እና ረዳቶቹ በስተቀር ለሌላ ለማንኛዉም ሰዉ ግልጽ
አይሆንም ። የተገኘዉ መረጃም ለታቀደለት አላማም ብቻ ይዉላል።
ሊያገኙዋቸዉ የሚችሉ ሰዎች
የዚህ ምርምር ፕሮጀክት በጎንደር ዩንቨርሲቲ የስነ ምግባር ኮሚቴ ታይቶ የሚጸድቅ
ይሆናል ። የትኛዉንም ዓይነት ጥያቄ መጠየቅ ቢፈልጉ ከዚህ ቀጥሉ የተጠቀሱትን
ግለሰቦች ማግኘት እና በማንኛዉም ጊዜ መጠየቅ ይችላሉ ።
1. ከፍያለዉ አዲስ ፡- ጎንደር ዩንቨርሲቲ ፤ጤና መኮነን ትምህርት ክፍል ፤ዋና
ተመራማሪ
የሞባይል ስልክ +251-09 20 25 66 99
ኢ-ሜል kefadis@gmail.com
2. ዶ/ር በላይነዉ ዋሴ ፡- ጎንደር ዩንቨርሲቲ፤ ህብረተሰብ ጤና አጠባበቅ ተቋም
የሞባይል ስልክ +251-09 13 47 43 98
ኢ-ሜል bewasie@gmail.com
3. አንሻ ነጋ ፡- ጎንደር ዩንቨርሲቲ፤ ህብረተሰብ ጤና አጠባበቅ ተቋም
የሞባይል ስልክ +251-09 18 15 10 73
ኢ-ሜል ains262000@gmail.com
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Annex 2- Data collection tool
Questionnaire prepared for collection of data on the patients ART or/and pre ART
medical registration book/chart to assess the incidence of Tuberculosis and
Predictors among adult living with HIV attending adult HIV care clinic at University of
Gondar Referral Hospital. Code No._____________
S. N. Part I: Socio demographic characteristics Skip
to Qn
101 Date of enrolment ----------/---------/-------- DD/MM/YY
102 Age at enrolment ------------- year
103 Sex 1. Male 2. Female
104 Marital status 1. Never married/ single
2. Married
3. Separated/ divorced
4. Widowed/er
5. Others (specify)----------------------
105 Level of education 1. No education
2. Primary
3. Secondary
4. Tertiary
5. Not recorded
106 Religion 1. Orthodox
2. Muslim
3. Protestant
4. Catholic
5. Others (specify) -------------------
107 Occupation 1. Employed
2. Unemployed
3. Not recorded
108 Address 1. Urban
2. Rural
3. Not recorded
109 Number of house hold ------------------persons
110 Disclosure status 1. Disclosed            2. Not disclosed
111 Addictions/Substance abuse 1. Tobacco     2.  Alcohol                3. drugs
Part II: Past Tuberculosis treatment history
201 Did the patient had past TB
treatment history?
1. Yes 3. Not recorded
2. No
2 or
3
301
202 Is the treatment completed? 1. Yes 2. No
203 Date treatment started -------/---------/-------- (DD/MM/YY)
204 Date treatment completed -------/---------/---------(DD/MM/YY)
Part III: HIV  care/ ART follow up
301 ART status 1. Pre-ART 2. ART
302 Date confirmed HIV+ ---------/------/------(DD/MM/YY)
303 ART Eligible date ---------/------/------(DD/MM/YY)
304 Eligible criteria 1. CD4 cell count                  3. Both
2. WHO clinical stage           4. Not recorded
305 Date ART started ---------/------/------(DD/MM/YY)
307 Initial Regimen 1. D4T/3TC/NVP
2. ZDV/3TC/NVP
3. D4T/3TC/EFV
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4. ZDV/3TC/EFV
5. Other (specify)-----------------
308 Was the Regimen changed? 1. Yes 2. No 231
0
309 When was it changed ---------/------/------DD/MM/YY
110 New regiment 1. First line 2. Second line
311 Reason for switch 1. side effects 3. TB
2. Pregnancy 4. Others -------------------
Part IV: Follow up form to be filled
M
on
th
s 
on
 A
R
T
Outcome
W
ei
gh
t(k
g)
H
ei
gh
t (
cm
)
Fu
nc
tio
na
l s
ta
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,B
)
W
H
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TB
 s
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IN
H
O
Is
C
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A
dh
 (G
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P) ART
C
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un
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H
gb
Al
iv
e
D
ea
d
D
ro
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ou
t
Tr
an
sf
er
 o
ut
St
op
Adh
(G,F,P
)
w
hy
Disp
ens
e
Side
effect
Reason
for
change
Initial
3
6
9
12
18
24
30
36
42
48
54
60
Last
visit
-------
/------
/------
If the patient Dead, drop out, transfer out or stop when was it occurs -----/-----/---DD/MM/YY?
401 Did the patient develop TB
during  follow up
a. Yes
b. No
402 When was it developed? ----------/----------/----------DD/MM/YY
403 During what was it
developed?
1. Pre ART     2. ART
404 What type of TB was it?
Name of data collectors -----------------------------sign ----------------date -----------------
Approved by -----------------------------sign -----------------------------date ----------------
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Annex -3 dummy tables
Table 1: socio demographic characteristics of patients on chronic HIV care at
University of Gondar Referral Hospital, from October, 2006 to December, 2007
Characteristics Number Frequency (%) Total
Age
15-29
30-44
>45
Sex
Male
Female
Marital Status
Never married
Married
Separated/divorced
Widowed
Religion
Orthodox
Muslim
Protestant
Catholic
Others
Educational status
No education
Primary
Secondary
Tertiary
Not recorded
Occupation
Employed
Unemployed
Not recorded
BMI
Underweight
Normal
Overweight
Obese
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Table 2: baseline clinical and immunological status of HIV patients on chronic
HIV care at University of Gondar Referral Hospital, from October, 2006 to
December, 2007
Characteristics Frequency Present (%) Total
ART eligible criteria
WHO clinical stage
CD4 count
Both
WHO clinical stage at
I-II
III
IV
Initial regimen
D4T/3TC/NVP
ZDV/3TC/NVP
D4T/3TC/EFV
ZDV/3TC/EFV
Others
Regimen change during follow
up
Yes
No
Developed side effect for ART
Yes
No
IPT provided
Yes
No
CPT provided
Yes
No
past TB treatment history
Yes
No
regimen switched to 2nd line
Yes
No
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Table 3: Tuberculosis incidence density rate stratified by baseline socio-
demographic and clinical characteristics of patients on chronic HIV care at
University of Gondar Referral Hospital, from October, 2006 to December, 2007.
Characteristics No.of
patients
Person-
years
No.with
TB
TB IDR (95%CI) p-value
Total patients
Age (years)
15-29
30-44
> 45
Sex
Male
Female
Occupation
Employed
Unemployed
Educational
status
Illiterate
Literate
Past History of
TB
Yes
No
Baseline CD4
cell count
(cells/µl)
<100
>100
Baseline
hemoglobin
(gm/dl)
<10
>10
WHO stage
Stage 1 or 2
Stage 3 or 4
IPT
Yes
No
CPT
Yes
No
TB, Tuberculosis ; IDR, Incidence density rate (per 100 person-years); CI,
confidence interval; IPT, Isoniazid preventive therapy; CPT, Cotrimoxazole
preventive therapy,
30
Table 2: Cox regression analysis of predictors of tuberculosis in HIV positive cohorts on
chronic HIV care at University of Gondar Referral Hospital; from October, 2006- January, 2012
No.
with TB
No.
with no
TB
Bivariate analysis Multivariate analysis
Variable CHR, (95%CI) P-value AHR, (95%
CI)
P-value
Age (in years)
15-29
30-44
>45
Sex
Male
Female
Occupation
Employed
Unemployed
Educational
Status
Illiterate
Literate
Baseline
Hemoglobin
(gm/dl)
<10
>10
Baseline CD4
cell count
<100 cells/µl
>100 cells/µl
WHO stage
Stage 1 or 2
Stage 3 or 4
Past history of
tuberculosis
Yes
No
IPT
Yes
No
CPT
Yes
No
Adherence
Good
Fair
Poor
HR=Hazard ratio, AHR= adjusted hazard ratio; CHR=Crude hazard ratio, CI= Confidence interval
Note: All variables with a P-value of <0.2 in bivariate analyses will be included in multivariate
analyses
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